Skyrizi (risankizumab-rzaa ... Note: After the Food and Drug Administration (FDA) approves a drug, it tracks and reviews side effects of the medication. Sharing your experience helps make ...

The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease ...

AbbVie’s Skyrizi, a biologic approved for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis, jumped from the 10th to fifth spot. The three that fell off the list ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Gov. Wes Moore made lowering drug costs a key campaign promise, making advocates of the law confident that their greatest ...

following a review of the company’s 2024 annual report and revised earnings forecasts. The report highlighted stronger-than-expected immunology sales, particularly from the drug Skyrizi.

AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for the treatment of obesity, from Danish research company, Gubra. While the ...

In Crohn's, Skyrizi, Stelara, and Ilumya are already approved by the FDA, while Tremfya is under review, having been submitted to the regulator last June. In the VIVID-1 trial, patients treated ...

The board’s executive director, Andrew York, said the body has been studying the affordability of six drugs — Jardiance, Ozempic, Farxiga, Trulicity, Skyrizi ... to a policy review process ...